Immune checkpoint inhibitors (ICIs) greatly enhanced cancer treatment, yet many patients are intrinsically resistant to anti-programed cell death protein 1 (anti-PD1) and anti-cytotoxic T-lymphocyte-associated protein 4 (anti-CTLA4) therapies or they become resistant after initial response. Here, PDCD1 is linked to cancer.